It has been reported that reduction in postprandial glucose peak levels by ACA in patients with type 2 diabetes reduces postprandial activation of the NF‐κB pathway in blood cells (Rudofsky et al., 2004). The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.